NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have decreased by 26.3% and is now trading at $1.91. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Clearside Biomedical.

Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings data on Friday, May, 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. The company had revenue of $4.10 million for the quarter, compared to the consensus estimate of $4 million. Clearside Biomedical had a negative net margin of 293.61% and a negative return on equity of 165.19%. View Clearside Biomedical's earnings history.

5 Wall Street analysts have issued 12 month target prices for Clearside Biomedical's shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Clearside Biomedical's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 214.1% from the stock's current price. View analysts' price targets for Clearside Biomedical.

News coverage about CLSD stock has trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clearside Biomedical earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutClearside Biomedical.

Clearside Biomedical saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,500,000 shares, a drop of 10.2% from the April 30th total of 1,670,000 shares. Based on an average daily trading volume, of 524,900 shares, the short-interest ratio is currently 2.9 days. Currently, 4.5% of the company's stock are short sold. View Clearside Biomedical's Current Options Chain.

Some companies that are related to Clearside Biomedical include Kamada (KMDA), Selecta Biosciences (SELB), Geron (GERN), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Urovant Sciences (UROV), OrganiGram (OGI), 89bio (ETNB), Osmotica Pharmaceuticals (OSMT), Lannett (LCI), MannKind (MNKD), Verastem (VSTM), Verrica Pharmaceuticals (VRCA), Bicycle Therapeutics (BCYC) and Avadel Pharmaceuticals (AVDL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Nabriva Therapeutics (NBRV), Amarin (AMRN), Immunomedics (IMMU), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP) and Proteostasis Therapeutics (PTI).

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Carmignac Gestion (4.41%), BlackRock Inc. (1.69%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.58%), Signaturefd LLC (0.27%) and Oxford Financial Group Ltd. (0.20%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Nancy J Hutson. View institutional ownership trends for Clearside Biomedical.

CLSD stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for Clearside Biomedical.

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Carmignac Gestion, Morgan Stanley, Oxford Financial Group Ltd., Signaturefd LLC, Geode Capital Management LLC, Jane Street Group LLC, Fred Alger Management LLC, and BlackRock Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay, and Nancy J Hutson. View insider buying and selling activity for Clearside Biomedical.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSD stock can currently be purchased for approximately $1.91.

Clearside Biomedical has a market capitalization of $85.70 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]